ZyVet Animal Health, a subsidiary of Zydus Pharmaceuticals, has introduced two FDA-approved generic medicines for animals in the US market. The first medicine, Phenylpropanolamine hydrochloride tablets, is used to treat urinary incontinence in dogs, a condition commonly affecting spayed females and older dogs. This medication works by addressing urethral sphincter hypotonus, a condition that leads to urinary incontinence. With this launch, veterinarians now have an affordable alternative for long-term management of the disorder.
The second medicine, Furosemide tablets, is used to manage congestive heart failure and chronic fluid retention in dogs and cats. Furosemide is a commonly prescribed diuretic that reduces edema and pulmonary congestion caused by cardiac, renal, or systemic disease. The approval of these generic medicines is expected to provide veterinarians with cost-effective treatment options for their patients.
The launch of these generic medicines comes as Zydus Lifesciences Ltd reported a net profit of ₹1,467 Crore for the quarter ended June 2025, a 3.3% increase from the previous corresponding period. The company’s revenue also registered a 6% year-over-year growth at ₹6,574 Crore, with an EBITDA of ₹2,089 Crore for the quarter.
The introduction of these generic medicines is a significant development for the animal health industry, as it provides veterinarians with affordable treatment options for common conditions affecting dogs and cats. The approval of these medicines by the FDA ensures their safety and efficacy, giving pet owners and veterinarians confidence in their use. With the growing demand for affordable and effective animal health treatments, ZyVet Animal Health’s launch of these generic medicines is a positive step forward for the industry.